NASDAQ: ELTX - Elicio Therapeutics, Inc.

Yield per half year: +6.53%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Elicio Therapeutics, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Elicio Therapeutics, Inc.

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers.

more details
It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers; ELI-008, a multivalent lymph node targeted AMP-peptide vaccine for mutant TP53-expressing cancers; ELI-005, a vaccine candidate for the prevention of COVID-19; ELI-011 for the treatment of hematological cancers; and ELI-012, a mKRAS TCR T cell AMP-lifier designs to use in combination with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company is headquartered in Boston, Massachusetts.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2021-02-05
ISIN US28657F1030
Industry Pharmaceuticals
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://elicio.com
Цена ао 8
Change price per day: +2.85% (4.92)
Change price per week: -2.5% (5.19)
Change price per month: -34.71% (7.75)
Change price per 3 month: -16.64% (6.07)
Change price per half year: +6.53% (4.75)
Change price per year: -45.18% (9.23)
Change price per 3 year: +156.85% (1.97)
Change price per year to date: +4.55% (4.84)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV -5.5 0
P/E 0 0
EV/EBITDA -1.13 0
Total: 2.5

Efficiency

Title Value Grade
ROA, % -187.61 0
ROE, % -170157.38 0
Total: 1.67

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.1335 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % 875.86 10
Yield Ebitda, % 190.23 10
Yield EPS, % 120.36 10
Total: 10
More

Institutions Volume Share, %
Vanguard Group Inc 174894 1.71
CM Management, LLC 50000 0.49
Geode Capital Management, LLC 44344 0.43
Renaissance Technologies, LLC 16466 0.16
Citadel Advisors Llc 14005 0.14
Meyer Handelman Co 13899 0.14
Bridgeway Capital Management, Inc. 12500 0.12
Tower Research Capital LLC (TRC) 2045 0.02
Steward Partners Investment Advisory, LLC 1554 0.02
Bank of America Corporation 1149 0.01



Head Job title Payment Year of birth
Mr. Robert T. Connelly CEO, President & Director 612k 1960 (65 years)
Dr. Christopher M. Haqq M.D., Ph.D. Executive VP, Head of Research & Development and Chief Medical Officer 589k 1966 (59 years)
Prof. Darrell J. Irvine Ph.D. Co-Founder, Consultant, Board Observer & Chairman of Scientific Advisory Board N/A
Mr. Michael DiVecchia Senior Vice President of Operations & Human Resources N/A
Dr. Peter DeMuth Ph.D. Chief Scientific Officer N/A 1986 (39 years)
Ms. Esther Welkowsky Senior Vice President of Clinical Development N/A
Ms. Joy Seymour VP & Head of Regulatory Affairs N/A
Ms. Megan C. Filoon General Counsel, Secretary & Compliance Officer N/A
Dr. Thian Kheoh Ph.D. Senior Vice President of Biometrics N/A

Address: United States, Boston. MA, 451 D Street - open in Google maps, open in Yandex maps
Website: https://elicio.com